Every biopharma team wrestles with the same three questions about Key Opinion Leaders:
* Who matters?
* When should you engage them?
* And how?
Just as important is deciding where each expert fits best, whether as a conference speaker, an advisory board member, or a long-term strategic partner. That call should rest on a proven track record, not a hunch.
The trouble is that most targeting still relies on one or two blunt metrics, like prescription volume or publication count. Both are useful, but neither tells the whole story. A physician who prescribes modestly or rarely publishes may still shape treatment decisions across an entire community.
Neolytica takes a broader approach. Our AI scans more than 100,000 digital sources, and every insight is validated by expert human review, drawing on 25 years of data science experience. The result is a clear picture of which KOLs matter, what they think, and how Medical Affairs, Commercial, and Market Access teams can make every interaction count.
Why Generic KOL Lists Fall Short
Syndicated databases hand every competitor the same list of names, so everyone ends up chasing the same handful of experts. And when prioritization rests on a single criterion, blind spots follow. A lower-volume HCP might anchor a dense local network, steer referral pathways, or quietly guide peers’ treatment choices, and never show up on a volume-based ranking.
Neolytica brings together prescription data, referral patterns, publications, clinical trials, congress appearances, and social media activity. This multidimensional view reveals real influence, so your teams reach the people who actually drive practice behavior.
Mapping the Full KOL Landscape with Ti Expert
Not every expert plays the same role. Ti Expert maps the entire KOL influence pyramid so you can focus on the critical 10–15% of KOLs who influence 60–70% of downstream HCPs, and avoid the cost and fatigue of over-engaging everyone else.
Combining technology with consulting, Ti Expert delivers validated data on each expert’s sphere of influence, professional relationships, and promotional activity across four tiers:
- Global and National KOLs shape scientific discourse, clinical guidelines, and global trial strategy.
- Community Opinion Leaders are regional and local clinical leaders with strong sway over Tier 2 and Tier 3 physicians. They’re often overlooked by strategies that fixate on national names.
- Rising Stars are high-potential experts still emerging in their field. Engage them early and you gain a first-mover advantage.
- Bridge Builders connect otherwise separate networks, carrying ideas and influence between them.
Beyond tiering, Ti Expert supports influence mapping, engagement planning, gap and landscape analysis, and message mapping.
Separating Credible Voices from Loud Ones
Online visibility isn’t the same as clinical credibility. Neolytica distinguishes Digital Opinion Leaders (DOLs), who are respected medical thought leaders active online, from general Social Media Influencers (SMIs), who may have reach but lack clinical standing. That distinction keeps your scientific exchange focused on voices that carry real weight with peers.
From Sentiment to Next Best Dialogue
Biopharma is moving away from mass outreach toward engagement shaped by each KOL’s sentiment, intent, and history. Neolytica turns complex signals into clear direction for the field:
- Multichannel monitoring tracks 100,000+ digital and press sources, plus congresses, publications, trials, and social platforms, capturing real-time sentiment on your brand and your competitors.
- AI with human validation means every AI-generated insight is reviewed by more than 300 medical experts before it reaches your field teams.
- Sentiment-based impact measurement shows how your medical communication is shifting opinion, not just how much share of voice it captures.
- Next Best Dialogue recommendations from My Insights translate sentiment shifts into guidance on what to discuss next and who is best placed to lead the conversation.
- NotifyMe real-time alerts deliver email updates and snapshots of recent and upcoming KOL activity in your therapeutic area, so your strategy can adapt as things happen.
The Right Audience, and No Surprises
For speaker programs and advisory boards, the audience matters as much as the speaker. Neolytica maps each KOL’s network to identify the physicians who will benefit most from a given educational event.
Ti Expert also flags any ties between KOLs and competitor brands, whether through events, co-authored publications, or clinical trials, so you plan every program with full context.
One Platform, Every Team, Fully Compliant
Neolytica brings four functions onto a single platform, with a strict firewall that keeps collaboration within regulatory lines:
- Medical Affairs connects R&D insight with the wider business.
- Commercial Marketing identifies and engages the opinion leaders who influence HCPs.
- Market Access gains early visibility into the expert voices that shape access decisions.
- Commercial Sales uses Rx data and referral patterns to fill the gaps in HCP approach strategy.
Specialized Support for Rare Diseases
In rare diseases, where patient populations are small and every expert relationship counts, Neolytica offers dedicated expertise in patient journey analysis, clinical trial enrollment, and KOL engagement for a successful launch.
Data Is Only the Start
Access to data isn’t the hard part. Knowing what to act on is. By pairing continuous AI signal detection with expert validation, Neolytica helps you:
- Look beyond prescription volume and publication counts
- Match each expert’s track record to the right role: speaker, advisory board member, or community advocate
- Concentrate effort on the 10–15% of KOLs who shape 60–70% of treatment behavior
- Equip field teams with real-time Next Best Dialogue guidance
- Reach unengaged Rising Stars before your competitors do
Ready to move beyond generic lists? See how Neolytica can sharpen your HCP targeting and build more meaningful KOL relationships at www.neolytica.ai.